trial · primary record
HT-101
Chronic Hepatitis B
| Phase | Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 60 |
| Primary completion | 2027-05 |
| Primary endpoint | Proportion of participants achieving HBsAg < lower limit of detection (LOD) 0.05 International Unit/mL (IU/mL) and HBV DNA < lower limit of quantitation (LLOQ) with or without anti-HBs seroconversion at W60 |
| Registry ID | NCT07245953 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:33:35.875Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07245953
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Ht-101 · compound